Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 3/20 | 0.35 |
| ▸ | CTSE | P14091 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838248 | 1.00 | CYP3A4 (0.41) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL12571933 | 0.94 | CYP3A4 (0.40) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL15047596 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL1687443 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL20684299 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL2734904 | 0.93 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL19490727 | 0.93 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL19372571 | 0.93 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL13034951 | 0.93 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL23652015 | 0.93 | CYP3A4 (0.41) | CYP3A4SSTR2FOLH1TTRREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3434275-A1 | ASSAY FOR CANCER CELLS BASED ON THE USE OF AURISTATIN CONJUGATES WITH ANTIBODIES | Seattle Genetics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2018-05-10 | — | — | US | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-2489364-B1 | Monomethylvaline compounds conjugated to antibodies | SEATTLE GENETICS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014134311-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140220047-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7498298-B2 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498298-B2 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009012268-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | CYP3A4 2414/4885SSTR2 2018/4885FOLH1 343/4885 |
| US-20140220047-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | CYP3A4 1668/4885SSTR2 2848/4885FOLH1 385/4885 |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | CYP3A4 1668/4885SSTR2 2848/4885FOLH1 385/4885 |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.